Opium (Opioid) Addiction (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction – Drugs In Development, 2021, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 13, 2, 34, 11 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 6 molecules, respectively.Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Adial Pharmaceuticals Inc

Alar Pharmaceuticals Inc

Amygdala Neurosciences Inc

Antheia Inc

Aoxing Pharmaceutical Company Inc

Aphios Corp

Aquilus Pharmaceuticals Inc

Astellas Pharma Inc

Atai Life Sciences BV

Benuvia Therapeutics Inc

BioCorRx Inc

BioXcel Therapeutics Inc

Bridge Therapeutics Inc

Bright Minds Biosciences Inc

Camurus AB

Cessation Therapeutics LLC

Closed Loop Medicine Ltd

Daisy Pharma Inc

Delpor Inc

DemeRx Inc

DMK Pharmaceuticals Inc

Elysium Therapeutics Inc

Emergent BioSolutions Inc

Ensysce Biosciences Inc

Eolas Therapeutics Inc

Epiodyne Inc

Ethismos Research Inc

Exxel Pharma Inc

Fab’entech SA

Fannin Partners LLC

Gilgamesh Pharmaceuticals Inc

Hunan Saiao Pharmaceutical Co Ltd

Indivior Plc

Inimmune Corp

Jazz Pharmaceuticals Plc

Kinoxis Therapeutics Pty Ltd

Lyndra Therapeutics Inc.

Mayne Pharma Group Ltd

Mebias Discovery LLC

Mind Medicine MindMed Inc

Nirsum Laboratories Inc

Omeros Corp

Opiant Pharmaceuticals Inc

Orexo AB

Orphomed Inc

Osmotica Pharmaceutical Corp

OYE Therapeutics Inc

Palisades Therapeutics

Pharmazz Inc

Phoenix PharmaLabs Inc

Plumb Pharmaceuticals LLC

Revive Therapeutics Ltd

SafeRX Pharmaceuticals Inc

Sen-Jam Pharmaceutical LLC

Senzer Ltd

Serina Therapeutics Inc

Syntropharma Ltd

Titan Pharmaceuticals Inc

VDM Biochemicals Inc

Vivreon Biosciences LLC

Yichang Humanwell Pharmaceutical Co Ltd

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Opium (Opioid) Addiction - Overview

Opium (Opioid) Addiction - Therapeutics Development

Opium (Opioid) Addiction - Therapeutics Assessment

Opium (Opioid) Addiction - Companies Involved in Therapeutics Development

Opium (Opioid) Addiction - Drug Profiles

Opium (Opioid) Addiction - Dormant Projects

Opium (Opioid) Addiction - Discontinued Products

Opium (Opioid) Addiction - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Opium (Opioid) Addiction – Pipeline by Adial Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Alar Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Amygdala Neurosciences Inc, 2021

Opium (Opioid) Addiction – Pipeline by Antheia Inc, 2021

Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, 2021

Opium (Opioid) Addiction – Pipeline by Aphios Corp, 2021

Opium (Opioid) Addiction – Pipeline by Aquilus Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Astellas Pharma Inc, 2021

Opium (Opioid) Addiction – Pipeline by Atai Life Sciences BV, 2021

Opium (Opioid) Addiction – Pipeline by Benuvia Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, 2021

Opium (Opioid) Addiction – Pipeline by BioXcel Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Bridge Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Bright Minds Biosciences Inc, 2021

Opium (Opioid) Addiction – Pipeline by Camurus AB, 2021

Opium (Opioid) Addiction – Pipeline by Cessation Therapeutics LLC, 2021

Opium (Opioid) Addiction – Pipeline by Closed Loop Medicine Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Daisy Pharma Inc, 2021

Opium (Opioid) Addiction – Pipeline by Delpor Inc, 2021

Opium (Opioid) Addiction – Pipeline by DemeRx Inc, 2021

Opium (Opioid) Addiction – Pipeline by DMK Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Elysium Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Emergent BioSolutions Inc, 2021

Opium (Opioid) Addiction – Pipeline by Ensysce Biosciences Inc, 2021

Opium (Opioid) Addiction – Pipeline by Eolas Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Epiodyne Inc, 2021

Opium (Opioid) Addiction – Pipeline by Ethismos Research Inc, 2021

Opium (Opioid) Addiction – Pipeline by Exxel Pharma Inc, 2021

Opium (Opioid) Addiction – Pipeline by Fab’entech SA, 2021

Opium (Opioid) Addiction – Pipeline by Fannin Partners LLC, 2021

Opium (Opioid) Addiction – Pipeline by Gilgamesh Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Hunan Saiao Pharmaceutical Co Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Indivior Plc, 2021

Opium (Opioid) Addiction – Pipeline by Inimmune Corp, 2021

Opium (Opioid) Addiction – Pipeline by Jazz Pharmaceuticals Plc, 2021

Opium (Opioid) Addiction – Pipeline by Kinoxis Therapeutics Pty Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Lyndra Therapeutics Inc., 2021

Opium (Opioid) Addiction – Pipeline by Mayne Pharma Group Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Mebias Discovery LLC, 2021

Opium (Opioid) Addiction – Pipeline by Mind Medicine MindMed Inc, 2021

Opium (Opioid) Addiction – Pipeline by Nirsum Laboratories Inc, 2021

Opium (Opioid) Addiction – Pipeline by Omeros Corp, 2021

Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Orexo AB, 2021

Opium (Opioid) Addiction – Pipeline by Orphomed Inc, 2021

Opium (Opioid) Addiction – Pipeline by Osmotica Pharmaceutical Corp, 2021

Opium (Opioid) Addiction – Pipeline by OYE Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Palisades Therapeutics, 2021

Opium (Opioid) Addiction – Pipeline by Pharmazz Inc, 2021

Opium (Opioid) Addiction – Pipeline by Phoenix PharmaLabs Inc, 2021

Opium (Opioid) Addiction – Pipeline by Plumb Pharmaceuticals LLC, 2021

Opium (Opioid) Addiction – Pipeline by Revive Therapeutics Ltd, 2021

Opium (Opioid) Addiction – Pipeline by SafeRX Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Sen-Jam Pharmaceutical LLC, 2021

Opium (Opioid) Addiction – Pipeline by Senzer Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Serina Therapeutics Inc, 2021

Opium (Opioid) Addiction – Pipeline by Syntropharma Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Pipeline by VDM Biochemicals Inc, 2021

Opium (Opioid) Addiction – Pipeline by Vivreon Biosciences LLC, 2021

Opium (Opioid) Addiction – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021

Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, 2021

Opium (Opioid) Addiction – Dormant Projects, 2021

Opium (Opioid) Addiction – Dormant Projects, 2021 (Contd..1)

Opium (Opioid) Addiction – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports